GCP
PACB icon

Gill Capital Partners’s Pacific Biosciences PACB Stock Holding History

Gill Capital Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29K Buy
+977
New +$1.75K ﹤0.01% 584

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gill Capital Partners's PACB Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Pacific Biosciences (PACB) in Q1 2026: 977 shares worth $1.29K. The stake represents ﹤0.01% of the portfolio and ranks #584 among its holdings.

229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Gill Capital Partners held 977 shares of Pacific Biosciences worth $1.29K as of Q1 2026.
  • Pacific Biosciences was a new Gill Capital Partners position in Q1 2026.
  • Pacific Biosciences made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #584 holding.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.